Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 288

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 8
Chunk 288
---
001

    Net loss

    —

    —

    —

    (85,403
    )

    (85,403
    )

    Unrealized gain (loss) on available-for-sale securities

    —

    —

    212

    —

    212

    Balance as of December 31, 2024

    5,859

    $
    1

    $
    1,957,261

    $
    8

    $
    (2,054,553
    )
     
    $
    (97,283
    )

See accompanying notes to the consolidated financial statements.

101

Atara Biotherapeutics, Inc.

Consolidated Statements of Cash Flows

(In thousands) 

    Year Ended December 31,

    2024

    2023

    Operating activities

    Net loss
     
    $
    (85,403
    )
     
    $
    (276,126
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Stock-based compensation expense

    27,001

    45,386

    Depreciation and amortization expense

    5,051

    4,829

    Accretion of liability related to sale of future revenues

    4,109

    4,792

    Non-cash operating lease expense

    12,126

    11,795

    Amortization (accretion) of investment premiums

    (240
    )

    792

    Other non-cash items, net

    (402
    )

    214

    Changes in operating assets and liabilities:

    Accounts receivable

    32,626

    6,113

    Inventories

    (4,434
    )

    (8,120
    )

    Other current assets

    (1,227
    )

    273

    Other assets

    19

    1,043

    Accounts payable

    687

    (3,130
    )

    Accrued compensation

    (4,930
    )

    (6,140
    )

    Accrued research and development expenses

    (9,380
    )

    (3,663
    )

    Other current liabilities

    (12,504
    )

    11,064

    Deferred revenue

    (20,303
    )